西班牙内科医学会和西班牙医学肿瘤学会就癌症患者继发血栓预防的共识声明

2020-09-08 西班牙内科协会(Spanish Society of Internal Medicine) Clin Transl Oncol . 2020 Sep 3. doi: 10.1007/s12094-020-02477-6

多达20%的癌症患者在临床过程中会出现静脉血栓栓塞性疾病(VTD)的某些表现。 VTD极大地影响发病率,死亡率,生活质量和药品支出。此外,在肿瘤患者中血栓复发和由VTD治疗引起的大出血的可能性更高。为

中文标题:

西班牙内科医学会和西班牙医学肿瘤学会就癌症患者继发血栓预防的共识声明

英文标题:

Consensus statement of the Spanish Society of Internal Medicine and the Spanish Society of Medical Oncology on secondary thromboprophylaxis in patients with cancer

发布日期:

2020-09-08

简要介绍:

多达20%的癌症患者在临床过程中会出现静脉血栓栓塞性疾病(VTD)的某些表现。 VTD极大地影响发病率,死亡率,生活质量和药品支出。此外,在肿瘤患者中血栓复发和由VTD治疗引起的大出血的可能性更高。为了决定将继发性血栓预防措施确定为这些患者的不确定治疗方法,重要的是要复查涉及的所有危险因素,无论是与疾病,患者还是先前的血栓事件有关。西班牙内科医学会(SEMI)和西班牙内科肿瘤医学(SEOM)达成共识的目的是建立有助于评估VTD复发风险的建议以及癌症患者的出血风险,以及分析现有药物的证据,这将有助于与知情患者建立共同决策的协议。

相关资料下载:
[AttachmentFileName(sort=1, fileName=66.pdf)] GetToolGuiderByIdResponse(projectId=1, id=96d9b1c001965afd, title=西班牙内科医学会和西班牙医学肿瘤学会就癌症患者继发血栓预防的共识声明, enTitle=Consensus statement of the Spanish Society of Internal Medicine and the Spanish Society of Medical Oncology on secondary thromboprophylaxis in patients with cancer, guiderFrom=Clin Transl Oncol . 2020 Sep 3. doi: 10.1007/s12094-020-02477-6, authorId=0, author=, summary=多达20%的癌症患者在临床过程中会出现静脉血栓栓塞性疾病(VTD)的某些表现。 VTD极大地影响发病率,死亡率,生活质量和药品支出。此外,在肿瘤患者中血栓复发和由VTD治疗引起的大出血的可能性更高。为, cover=, journalId=0, articlesId=null, associationId=1917, associationName=西班牙内科协会(Spanish Society of Internal Medicine), associationIntro=Spanish Society of Internal Medicine, copyright=0, guiderPublishedTime=Tue Sep 08 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<p>多达20%的癌症患者在临床过程中会出现静脉血栓栓塞性疾病(VTD)的某些表现。 VTD极大地影响发病率,死亡率,生活质量和药品支出。此外,在肿瘤患者中血栓复发和由VTD治疗引起的大出血的可能性更高。为了决定将继发性血栓预防措施确定为这些患者的不确定治疗方法,重要的是要复查涉及的所有危险因素,无论是与疾病,患者还是先前的血栓事件有关。西班牙内科医学会(SEMI)和西班牙内科肿瘤医学(SEOM)达成共识的目的是建立有助于评估VTD复发风险的建议以及癌症患者的出血风险,以及分析现有药物的证据,这将有助于与知情患者建立共同决策的协议。</p>, tagList=[TagDto(tagId=516, tagName=癌症)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=20620, categoryName=肿瘤医学网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=2105, appHits=35, showAppHits=0, pcHits=465, showPcHits=2070, likes=0, shares=1, comments=3, approvalStatus=1, publishedTime=Mon Sep 07 16:16:43 CST 2020, publishedTimeString=2020-09-08, pcVisible=1, appVisible=1, editorId=4754896, editor=fbzhang, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=fbzhang, createdTime=Mon Sep 07 16:14:52 CST 2020, updatedBy=4754896, updatedName=fbzhang, updatedTime=Sat Jan 06 20:05:43 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=66.pdf)])
66.pdf
下载请点击:
评论区 (2)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=956210, encodeId=b3da95621025, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12d22296338, createdName=121f8ba0m90暂无昵称, createdTime=Mon Apr 12 17:19:21 CST 2021, time=2021-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895108, encodeId=ddff89510882, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/41C3A62A59564EB65D498614621E966F/100, createdBy=539f1963836, createdName=武亚晶, createdTime=Wed Oct 28 15:20:14 CST 2020, time=2020-10-28, status=1, ipAttribution=)]
    2021-04-12 121f8ba0m90暂无昵称

    学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=956210, encodeId=b3da95621025, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12d22296338, createdName=121f8ba0m90暂无昵称, createdTime=Mon Apr 12 17:19:21 CST 2021, time=2021-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895108, encodeId=ddff89510882, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/41C3A62A59564EB65D498614621E966F/100, createdBy=539f1963836, createdName=武亚晶, createdTime=Wed Oct 28 15:20:14 CST 2020, time=2020-10-28, status=1, ipAttribution=)]
    2020-10-28 武亚晶

    学习

    0